Budesonide Inhaler Market Set To Grow From $7.45 Billion In 2026 To $10.25 Billion By 2030 At A CAGR Of 8.3%
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Budesonide Inhaler Market Size, Value And Growth Trends Through 2030
The budesonide inhaler industry has experienced significant expansion over the last few years. Its market valuation is projected to increase from $6.88 billion in 2025 to $7.45 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.3%. Factors driving this historical growth include rising cases of asthma, higher rates of COPD detection, broader use of corticosteroid inhalers, an enlarged capacity for hospital-based respiratory treatment, and a growing number of respiratory conditions linked to smoking.
The market for budesonide inhalers is projected to experience significant expansion over the coming years, reaching an estimated $10.25 billion by 2030 with a compound annual growth rate (CAGR) of 8.3%. This upward trajectory during the forecast period is fueled by factors such as the rising prevalence of chronic respiratory conditions, the advancement of smart inhaler technologies, the expansion of outpatient respiratory care services, a heightened emphasis on preventive asthma management, and growing demand in emerging economies. Key developments shaping this period include a growing preference for sustained respiratory control, wider adoption of combination inhaler therapies, an increase in home-based respiratory care, expanded use among pediatric and elderly populations, and ongoing efforts to enhance inhaler drug delivery efficiency.
Download A Free Sample Report For Comprehensive Market Insights:
Budesonide Inhaler Market Growth Factors Supporting Long-Term Expansion
The growing occurrence of respiratory conditions is anticipated to boost the expansion of the budesonide inhaler market in the coming years. These conditions, which impact the lungs and airways, often result in breathing difficulties and are typically accompanied by symptoms like coughing, wheezing, and shortness of breath. They encompass asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and various lung infections. An increase in these disorders is largely attributed to rising air pollution, which heightens exposure to harmful pollutants that irritate the airways and compromise lung function. Budesonide inhalers are utilized to manage such conditions by delivering anti-inflammatory medication directly to the lungs, providing sustained control. Their portable design ensures ease of use and carriage, helping to reduce flare-ups and enhance respiratory well-being. As a case in point, in June 2025, Public Health Wales, a UK-based National Health Service organization, reported that the number of patients listed on asthma and COPD registers in Wales is forecasted to grow over the next decade. Specifically, asthma cases are expected to climb from 237,400 in 2023-24 to over 256,000 registered cases, while COPD cases are projected to rise from 75,600 to more than 84,000 in the same period. Consequently, the rising prevalence of respiratory disorders is fueling progress in the budesonide inhaler market.
Budesonide Inhaler Market Categorization By Product Type And Application
The budesonide inhaler market covered in this report is segmented –
1) By Product Type: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizers, Combination Inhalers
2) By Dosage Form: Aerosols, Dry Powder, Suspension, Spray
3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis
4) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Pharmacies
Subsegments:
1) By Metered-Dose Inhalers: Pressurized Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Compatible Metered-Dose Inhalers, Hydrofluoroalkane Propellant-Based Metered-Dose Inhalers
2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Capsule-Based Dry Powder Inhalers, Reservoir-Based Dry Powder Inhalers
3) By Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Homecare Nebulizers, Hospital-Use Nebulizers
4) By Combination Inhalers: Budesonide And Formoterol Inhalers, Budesonide And Salmeterol Inhalers, Budesonide, Glycopyrrolate, And Formoterol Inhalers, Budesonide And Vilanterol Inhalers
Budesonide Inhaler Market Industry Trends Shaping Future Revenue Growth
Major players within the budesonide inhaler sector are concentrating their efforts on bringing innovative products to market, particularly generic ones, as a means to enhance affordability and broaden patient access to respiratory treatments. Generic inhaled medications are unbranded versions that deliver identical active ingredients, dosages, and therapeutic outcomes as their branded equivalents, usually at reduced costs. For example, in July 2023, the US-based pharmaceutical company Viatris Inc., working alongside Kindeva Drug Delivery L.P., also US-based, released Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol—the very first generic of Symbicort to receive approval from the Food and Drug Administration (FDA). This drug-device combination is indicated for asthma and chronic obstructive pulmonary disease (COPD); it operates by decreasing airway inflammation via budesonide while formoterol loosens the muscles surrounding the airways, thus giving patients a less expensive treatment option.
Budesonide Inhaler Market Company Landscape And Strategic Competition
Major companies operating in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.
Access The Complete Budesonide Inhaler Market Report:
Budesonide Inhaler Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the budesonide inhaler market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the budesonide inhaler market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
